Obstructive hypertrophic cardiomyopathy: a review of new therapies.
Mehra N, Ali AH, Desai MY.
Future Cardiol. 2023 Oct;19(13):661-670. doi: 10.2217/fca-2023-0056. Epub 2023 Nov 7.
Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.
Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH.
J Am Coll Cardiol. 2021 Dec 21;78(25):2505-2517. doi: 10.1016/j.jacc.2021.07.065.
New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy.
Woodland M, Al-Horani RA.
Cardiovasc Hematol Agents Med Chem. 2023;21(2):78-83. doi: 10.2174/1871525721666221019095218.
Interventions in Hypertrophic Obstructive Cardiomyopathy.
Ding WY, Meah MN, Stables R, Cooper RM.
Can J Cardiol. 2024 May;40(5):833-842. doi: 10.1016/j.cjca.2023.12.001. Epub 2023 Dec 8.
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.
Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, Garcia-Pavia P, Lakdawala NK, Nagueh SF, Rader F, Tower-Rader A, Turer AT, Coats C, Fifer MA, Owens A, Solomon SD, Watkins H, Barriales-Villa R, Kramer CM, Wong TC, Paige SL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham T; REDWOOD-HCM Steering Committee and Investigators.
J Am Coll Cardiol. 2023 Jan 3;81(1):34-45. doi: 10.1016/j.jacc.2022.10.020.
Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy.
Sorajja P, Fraser R, Steffen R, Harris KM.
Interv Cardiol Clin. 2022 Jul;11(3):245-255. doi: 10.1016/j.iccl.2022.03.001.
Aficamten for Obstructive Hypertrophic Cardiomyopathy.
Pedreira-Bouzas J, Pousada-Fonseca Á, Fraga D.
N Engl J Med. 2024 Aug 15;391(7):665. doi: 10.1056/NEJMc2408094.
Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy.
Dalo JD, Weisman ND, White CM.
Ann Pharmacother. 2023 Apr;57(4):489-502. doi: 10.1177/10600280221117812. Epub 2022 Aug 11.
Obstructive hypertrophic cardiomyopathy.
Graham-Cryan MA, Rowe G, Hathaway L, Biddle S, Tripodi D, Fananapazir L.
Prog Cardiovasc Nurs. 2004 Fall;19(4):133-40. doi: 10.1111/j.0889-7204.2003.03400.x.
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM.
Masri A, Barriales-Villa R, Elliott P, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Heitner SB, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Saberi S; on behalf of the FOREST‐HCM Investigators.
Eur J Heart Fail. 2024 Sep;26(9):1993-1998. doi: 10.1002/ejhf.3372. Epub 2024 Jul 18.
